Item 7.01 Regulation FD Disclosure

Lexaria Bioscience Corp. disclosed the results of its animal study evidencing the improved oral delivery of the Protease Inhibitor, Darunavir and the Reverse Transcriptase Inhibitor, Efavirenz, using the Company's patented DehydraTECH technology. A table setting out the improved drug delivery results is below:





                           AUClast*                AUC?** Delivery &
  Drug      Drug Class    Delivery &     Control      Improvement      Control
                          Improvement   (hr·ng/mL)     (hr·ng/mL)     (hr·ng/mL)
                           (hr·ng/mL)

Darunavir    Protease     721 ± 332    469 ± 252      726 ± 211       536 ± 223
            Inhibitor        54%                         35%
                           (p=0.036)                   (p=0.062)

Efavirenz Non-nucleoside  752 ± 203     650 ± 148      1072 ±40       757 ±103
             Reverse         16%                         42%
          Transcriptase    (p=0.11)                    (p=0.028)
            Inhibitor

Full details regarding the animal study are disclosed in the Company's news release which is attached as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

© Edgar Online, source Glimpses